AstraZeneca faces potential fines in China
AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China,
AstraZeneca shares rise
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
(Reuters) -Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
GlobalData on MSN8h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialResearchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback